KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$127.0 million.

  • Vir Biotechnology's Net Cash Flow fell 14036.26% to -$127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.1 million, marking a year-over-year increase of 5910.3%. This contributed to the annual value of $57.4 million for FY2024, which is 10946.19% up from last year.
  • Per Vir Biotechnology's latest filing, its Net Cash Flow stood at -$127.0 million for Q3 2025, which was down 14036.26% from -$61.7 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Net Cash Flow ranged from a high of $690.9 million in Q2 2022 and a low of -$542.7 million during Q3 2022
  • Moreover, its 5-year median value for Net Cash Flow was -$52.8 million (2024), whereas its average is -$14.3 million.
  • The largest annual percentage gain for Vir Biotechnology's Net Cash Flow in the last 5 years was 45244.19% (2022), contrasted with its biggest fall of 181603.88% (2022).
  • Quarter analysis of 5 years shows Vir Biotechnology's Net Cash Flow stood at -$364.2 million in 2021, then surged by 68.15% to -$116.0 million in 2022, then plummeted by 81.95% to -$211.1 million in 2023, then skyrocketed by 125.76% to $54.4 million in 2024, then tumbled by 333.65% to -$127.0 million in 2025.
  • Its Net Cash Flow was -$127.0 million in Q3 2025, compared to -$61.7 million in Q2 2025 and $49.3 million in Q1 2025.